Back to mobile site

Nektar Therapeutics (NKTR) Tops Q1 EPS by 9c

May 3, 2016 4:39 PM EDT

Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $58.9 million versus the consensus estimate of $43.78 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings